Drugs / Levodopa/Carbidopa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00562198 | Jan → Feb 2008 | Parkinson disease | Orion Corporation, Orion Pharma | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2009-02-24 | Orion Corporation, Orion Pharma | Results Orion: Primary objective of STRIDE-PD study was not achieved orionpharma.com ↗
The primary endpoint was the time to onset of dyskinesia. |
| 2008-01-24 | Orion Corporation, Orion Pharma | Results Positive primary endpoint from FIRST-STEP study with Stalevo in early Parkinson's Disease orionpharma.com ↗
The treatment difference was statistically significant (p<0.05) in favour of Stalevo. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-02-24 | Orion Corporation, Orion Pharma | Orion: Primary objective of STRIDE-PD study was not achieved orionpharma.com ↗ |
| 2008-01-24 | Orion Corporation, Orion Pharma | Positive primary endpoint from FIRST-STEP study with Stalevo in early Parkinson's Disease orionpharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levodopa/Carbidopa | “Effects of Single Doses of Stalevo 200 and Levodopa/Carbidopa 200/50mg on Striatal 11C-Raclopride Binding Potential in Parkinson's Disease Patients With Wearing-Off Symptoms;an...” NCT00562198 ↗ |